title: Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.
abstract: The primary objective of this study was to determine the proportion of patients exhibiting a radiographic response in a cohort of patients with recurrent malignant glioma who were treated with irinotecan. Secondary objectives were to determine progression-free survival, overall survival, and toxicity. The trial was terminated after the first 18 patients were enrolled in this multicenter, 2-stage, phase 2 study. Twelve patients received concurrent enzyme-inducing antiepileptic drugs, and 6 did not. Each cycle consisted of a 90-min i.v. infusion of irinotecan every week for 4 consecutive weeks, followed by 2 weeks off. One patient had a complete response, 5 patients had stable disease, 5 patients had radiographic progression, 6 patients were removed from the study because of toxicity, and 1 patient refused further therapy and was removed from the study. The response rate in this study was 6% (1/18), and 28% (5/18) of these patients progressed while receiving irinotecan. Dose-limiting toxicities consisted of diarrhea in 5 patients, neutropenia in 1 patient, infection in 1 patient, and respiratory failure in 1 patient. Irinotecan had minimal efficacy in this cohort of 18 patients with recurrent malignant glioma. Toxicity was significant but similar to that reported in other patient populations.
authors.affiliation: Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA.
authors.forename: Tracy T
authors.initials: TT
authors.lastname: Batchelor
authors.forename: Mark R
authors.initials: MR
authors.lastname: Gilbert
authors.forename: Jeffrey G
authors.initials: JG
authors.lastname: Supko
authors.forename: Kathryn A
authors.initials: KA
authors.lastname: Carson
authors.forename: Louis B
authors.initials: LB
authors.lastname: Nabors
authors.forename: Stuart A
authors.initials: SA
authors.lastname: Grossman
authors.forename: Glenn J
authors.initials: GJ
authors.lastname: Lesser
authors.forename: Tom
authors.initials: T
authors.lastname: Mikkelsen
authors.forename: Surasak
authors.initials: S
authors.lastname: Phuphanich
mesh_terms: D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002166:Camptothecin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D016001:Confidence Intervals; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D000077146:Irinotecan; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate
chemical_list: D000077146:Irinotecan; D002166:Camptothecin